Click to close

Contact us

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Request a Demo

Please complete the required fields.

*Required Fields

Request a Demo

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Report Problem

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Login

Click to close

Please complete the required fields.

Forgot your password? Register

Tell us your email address and we'll send you instructions on how to reset your password.

Click to close

Resolution not supported

Click to close

Saving...

 0%

Institutul de Pneumoftiziologie Marius Nasta

Şoseaua Viilor 90, Sector 5, Bucureşti, Bucureşti - Ilfov
050159
Romania
Website | ViS Profile

Center Profile Completeness

About
- Center
- Location
Infrastructure
- General
- Disease-Specific
Patients
- General
- Disease-Specific
Team
- Personnel
- Investigators
Expertise
- General
- Disease-Specific
Research
- Trials
- Publications
Network
- Disease-Specific

Trials in this area

- Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (GlaxoSmithKline; NCT01054885; Year 2009)

- The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 Mcg Once Daily Compared With Tiotriopium 18 Mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD. (GlaxoSmithKline; NCT01777334; Year 2013)

- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study (Novartis Pharmaceuticals; NCT01782326; Year 2013)

Investigators in this area

  • Miron Bogdan
  • Florin Mihaltan
  • Roxandra Ulmeanu
  • Paul Stoicescu

Diseases in this area

  • Sleep Apnea
  • COPD
  • Sinusitis
  • Asthma
  • Pulmonary Embolism
  • Pulmonary Vascular Disorder
  • Pulmonary Hypertension
  • Peripheral Vascular Disease

Click to close
Click to close

Add to network